Loading the records…
Loading the records…
S.4066 is early-stage legislation targeting mifepristone. No direct market impact identified. Direct public company exposure is minimal, limited to one CDMO with a small contract, and no market-moving impact is expected at this procedural stage.
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
No market implications at this stage. The bill does not authorize spending, name any public company, or create a financial mechanism that would affect sectors or tickers. Investors should monitor this bill only for progression beyond committee referral, which is unlikely in the near term.
S.4066, the Safeguarding Women from Chemical Abortion Act, was introduced in the Senate on March 11, 2026, and referred to the Committee on Health, Education, Labor, and Pensions. The bill seeks to withdraw FDA approval of mifepristone for pregnancy termination and establish a federal tort for harm caused by chemical abortion drugs. It is in the earliest legislative stage with only two actions taken. No funding is authorized or appropriated. A companion bill (HR7902) exists in the House but also remains in early committee referral. No specific public companies are directly named or materially impacted by this bill. The single CDMO with a small mifepristone contract is not identified in available data, and the contract value is immaterial to any public company's revenue. No real market data was provided to analyze price trends. The bill faces a long legislative path with low probability of near-term passage, as it must clear committee, pass both chambers, and be signed into law.
Matched on shared policy language across AI analyses, with ticker & timing weight
SAVE Moms and Babies Act of 2026
To provide that the approved application under the Federal Food, Drug, and Cosmetic Act for the drug mifepristone for the purpose of the termination of intrauterine pregnancy is deemed to have been withdrawn, to establish a Federal tort for harm to women caused by chemical abortion drugs, and for other purposes.
Chemical Abortion Risk Awareness Act
Executive orders & memoranda affecting the same sectors or companies
This executive order establishes a Women's Health Division within the NIH to coordinate and accelerate research on understudied women's health conditions, and creates a White House Women's Health Task Force to drive policy reforms and translation of research into clinical practice across federal agencies. It directs specific agencies to prioritize research, data collection, and translation into prevention, diagnosis, and treatment, with a focus on all life stages from infancy through aging.
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
This proclamation orders the Secretaries of War and Veterans Affairs to mandate rapid, ongoing digital sharing of military personnel and medical records, deploy AI-powered tools for benefits applications, and update existing IT contracts for interoperability. It also requires the Transition Assistance Program to connect separating service members to specific jobs or training programs before discharge.
Free — no credit card
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →